The 169-acre site offers API manufacturing for oligonucleotides, peptides & conjugates at any scale.
When combining the peptide capacity in our Changzhou site, the total reactor volume of solid-phase peptide synthesizers at WuXi TIDES has reached over 41,000 L. To meet the growing customer needs, we plan to add more peptide manufacturing capacities soon.
In 2025, Taixing site successfully passed US FDA pre-approval inspection for an innovative peptide drug.
